Compare Johnson & Johnson (JNJ) vs McCormick & Company, Incorporated (MKC) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

MKC trades at $52.26, up 1.08% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong profitability with a 21.91% net income margin and a low P/E of 8.6, suggesting potential undervaluation. Recent Q2 2026 earnings beat expectations, and the pending Unilever Foods deal is a key strategic focus. Cash flow from operations remains robust at $962.2 million for 2025, though net cash flow was negative $90.2 million due to financing activities.

The outlook is mixed; analyst consensus is a buy with a $59.67 price target, implying 14% upside, but technicals and modest organic growth pose risks. The transformative Unilever deal offers growth potential, yet execution risks and competitive pressures in consumer segments warrant caution. Debt reduction trends are positive, with debt-to-asset ratio improving to 30.34% in 2025.